Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.45 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906647 | 1.00 | GRIK1 (0.54) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Trifluoroacetic Acid SCHEMBL30191327 | 0.88 | GRIK1 (0.44) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL13913802 | 0.81 | DPP9 (0.39) | GRIK1SLC7A5GRIK2 | |
| SCHEMBL13913742 | 0.81 | DPP9 (0.39) | GRIK1SLC7A5GRIK2 | |
| SCHEMBL1768449 | 0.77 | GSR (0.58) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL197385 | 0.77 | GSR (0.58) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL3096327 | 0.77 | ALDH1A1 (0.39) | GRIK1 | |
| SCHEMBL1768719 | 0.77 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL1768717 | 0.77 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL16027034 | 0.77 | GRIK1 (0.42) | GRIK1SLC7A5GRIK2GRM1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56034608-A | — | — | None | — | — | JP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024073605-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC. (JP) | 2024-04-04 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-6194143-B1 | MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-02-27 | — | — | US | disclosed |
| US-6057287-A | KUNITZ DOMAIN HAVING DISULFIDE BONDS AT CYSTINE 5-55, 14-38, 30-51 POSITIONS | DYAX CORP. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0948640-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029562-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-07-09 | — | — | WO | disclosed |
| EP-0388109-B1 | Potato Production | KOREA INST SCI & TECH (KR) | 1995-03-15 | — | — | EP | disclosed |
| EP-0388109-A1 | Potato Production | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1990-09-19 | — | — | EP | disclosed |
| US-4749716-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| US-4554007-A | Geometrical isomer of 1-substituted-1-triazolylstyrenes, and their production and use as fungicide, herbicide and/or plant growth regulant | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-19 | — | — | US | disclosed |
| JP-S5634608-A | PREPARATION FOR CONTROLLING LAWN PYTHIUM PATCH | BIHOU SHOKAI:KK | 1981-04-06 | — | — | JP | disclosed |
| US-4244731-A | APPLYING A CARBOXY DERIVATIVE OF A 2,6-DIMETHYLPHENOXY COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | GRIK1 1342/4885SLC7A5 3300/4885GRIK2 1549/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRIK1 2914/4885SLC7A5 75/4885GRIK2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.